ArticleFrontiers in immunology2025
Development and validation of nomogram for predicting pathological complete response to neoadjuvant chemotherapy and immunotherapy for locally advanced gastric cancer: a multicenter real-world study in China.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The combination of neoadjuvant chemotherapy and immunotherapy (NICT) brings a higher proportion of pathological complete response (pCR) compared with neoadjuvant chemotherapy for locally advanced gastric cancer (LAGC). Here we constructed and validated a prediction model to provide a clinical reference for predicting pCR. Methods: 456 patients who accepted radical gastrectomy after NICT in seven large-scale gastrointestinal medical centers from Jan 2020 to Jan 2025 were enrolled in this study, with 320 patients in the training set and 136 patients in the validation set. The uni- and multivariate logistic regression model were used to evaluate the factors influencing pCR and a nomogram model was constructed. The area under the receiver operating characteristic curve (AUC), the calibration curve and decision curve analysis (DCA) were used to evaluate the discrimination, accuracy and clinical value of the nomogram model. Results: There was no significant difference in the baseline characteristics between training and validation set. The pCR and MPR rates were respectively 16.2% and 39.5%. Complete response by abdominal enhanced CT, less diameter of tumor bed, non-signet-ring cell, ages≥70 years old, and CEA<4.25 ng/mL were proved as the independent predictors for pCR (P<0.05). The nomogram model showed that the AUC (95%CI) predicting the pCR were 0.862 (95% CI: 0.807-0.916) in the training set and 0.934(95%CI: 0.889-0.979) in the validation set. The calibration curves showed that the prediction curve of the nomogram was good in fit with the actual pCR in the training and validation set respectively (Hosmer-Lemeshow test: χ2 = 9.093, P=0.168; χ2 = 2.853, P=0.827). Decision curve analysis showed a good outcome to assess net benefit. Conclusion: Our nomogram model could provide satisfactory predictive effect for the pCR in LAGC patients with NICT, which proves to be a valuable approach for surgeons to make personalized strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.